hrp0094p1-21 | Diabetes A | ESPE2021

Incidence of Type 1 Diabetes in Children and Adolescents during the Covid-19 Pandemic in Germany: Results from the DPV registry

Kamrath Clemens , Rosenbauer Joachim , Eckert Alexander , Siedler Kai , Bartelt Heike , Klose Daniela , Sindichakis Marina , Herrlinger Silke , Lahn Valentina , Holl Reinhard W. ,

Objective: The aim of this study was to investigate the incidence of type 1 diabetes in children and adolescents during the Covid-19 pandemic in Germany compared to previous years.Research Design and Methods: Based on data from the multicenter German Diabetes Prospective Follow-up Registry (DPV), we analyzed the incidence of type 1 diabetes per 100,000 patient years in children and adolescents in the year 2020. Using Poisson regression m...

hrp0097fc5.1 | Diabetes and insulin 1 | ESPE2023

Diabetes mellitus and gender incongruence: Worse metabolic control in type 1 and higher mental health issue rates in type 1 and 2 diabetes – a DPV registry study

Boettcher Claudia , R. Tittel Sascha , Reschke Felix , Fritsch Maria , Schreiner Felix , Achenbach Maike , Thiele-Schmitz Susanne , Gillessen Anton , Nellen-Hellmuth Nicole , Golembowski Sveb , W. Holl Reinhard

Background: The condition when a person’s gender identity does not match the gender assigned at birth is called gender incongruence (GI). GI numbers increased tremendously over the last decade. Diabetes mellitus – type 1 and type 2 – is a severe and lifelong disease. GI combined with diabetes may potentiate the burden for affected people.Objective: The study aimed to characterize people with GI and diab...

hrp0097fc9.2 | Diabetes and insulin 2 | ESPE2023

Characterization of pediatric patients with type 2 diabetes and trends in their pharmaceutical management 2000-2022 in German-speaking countries: Analysis based on the DPV registry

Becker Marianne , Wiegand Susanna , Schmid Stefanie , Weghuber Daniel , Weihrauch-Blüher Susann , Reinehr Thomas , Kapellen Thomas , Tauschmann Martin , Denzer Christian , Körner Antje , W Holl Reinhard

Introduction: The prevalence of pediatric type 2 diabetes (T2D) increased over the last 2 decades, related to the rise in obesity. Meanwhile, treatment options for T2D have evolved considerably. Therefore, we analyzed changes in treatment approaches for pediatric T2D over two decades.Material and Methods: Patients with T2D from 321 pediatric diabetes centers (Austria 24, Switzerland 2, Luxemburg 1, Germany 290) were reco...

hrp0097t2 | Section | ESPE2023

Effects of tiratricol treatment withdrawal in MCT8 deficiency: ReTRIACt Trial

Freund Matthijs , Chatterjee Krishna , van Geest Ferdy , van der Most Floor , Bowers Dominic , Persson Anders , J Bauer Andrew , Edward Visser W.

We introduce the ReTRIACt Trial (NCT05579327) of tiratricol (Triac) for MCT8-deficiency, a rare X-linked disease resulting from disordered thyroid hormone transport and characterized by profound neurodevelopmental delay and features of chronic peripheral thyrotoxicosis. The ReTRIACt Trial aims to verify the effects of tiratricol observed in previous studies. It is a double-blind, randomized, multicenter, placebo-controlled study to evaluate the effects of tiratricol discontinu...

hrp0097p1-401 | Adrenals and HPA Axis | ESPE2023

Impact of Newborn Screening for Congenital Adrenal Hyperplasia (CAH) on Adult Height: Data from the CAH Registry of the German Society for Pediatric and Adolescent Endocrinology and Diabetology (DGPAED).

Hoyer-Kuhn Heike , Eckert Alexander , Binder Gerhard , Bonfig Walter , Dübbers Angelika , Mohnike Klaus , Riedl Stefan , Wölfle Joachim , G Dörr Helmut , W Holl Reinhard

Objective: The treatment of children with classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency (CAH) is a challenge since both undertreatment and overtreatment with glucocorticoids can affect growth. Numerous reports in the literature have shown that the linear growth of individuals with CAH is affected and adult height is compromised. However, most of these data were obtained in the era before CAH newborn screening....

hrp0092fc15.1 | Late Breaking Abstracts | ESPE2019

DLG2 Mutations in Patients with Delayed or Absent Puberty

Jee Youn Hee , Won Sehoon , Lui Julian C. , Jennings Melissa , Whalen Philip , Yue Shanna , Cheetham Tim , Boden Matthew G. , Radovick Sally , Quinton Richard , Leschek Ellen W. , Aguilera Greti , Yanovski Jack A. , Seminara Stephanie B. , Roche Katherine W. , Crowley William F. , Delaney Angela , Baron Jeffrey

NMDA (N-Methyl-D-aspartic acid) receptors have been shown to control the timing of sexual maturation in laboratory animals. Therefore, variants in genes impacting NMDA receptor signaling might be predicted to affect human puberty. We studied an extended family with extremely delayed puberty (menarche at 16.5 - 18 years for female family members and pubertal onset at 16 years for male family members). Exome sequencing revealed a rare missense variant (F900V) in DLG2, w...

hrp0084p2-406 | GH & IGF | ESPE2015

Metabolic Health in Short Children Born Small for Gestational Age Treated with GH and GnRHa: Results of a Randomised, Dose-response Trial

van der Steen M , Lem A J , van der Kaay D C M , Waarde W M Bakker-van , van der Hulst F J P C M , Neijens F S , Noordam C , Odink R J , Oostdijk W , Schroor E J , Sulkers E J , Westerlaken C , Hokken-Koelega A C S

Background: Previously we showed that pubertal children born small for gestational age (SGA) with a poor adult height (AH) expectation can benefit from treatment with GH 1 mg/m2 per day (~0.033 mg/kg per day) in combination with 2 years of GnRH analogue (GnRHa) and even more so with a double GH dose. GnRHa treatment is thought to have negative effects on body composition and blood pressure. Long-term effects and GH-dose effects on metabolic health in children treate...

hrp0092p2-36 | Bone, Growth Plate and Mineral Metabolism | ESPE2019

A 10-year-old Girl with Primary Hypoparathyroidism and Systemic Lupus Erythematosus (SLE)

Borysewicz-Sanczyk Hanna , Sawicka Beata , Michalak Justyna , Wójtowicz Jerzy , Dobrenko Elzbieta , Konstantynowicz Jerzy , Kemp Elizabeth , Thakker Rajesh , Allgrove Jeremy , Black Sarah , Chen Shu , Furmaniak Jadwiga , Rees Smith Bernard , Bossowski Artur

Introduction: Parathyroid Hormone (PTH) is one of the principal regulatory hormones for calcium and phosphate homeostasis. Reduced PTH concentration in hypoparathyroidism is characterised by hypocalcaemia and hyperphosphataemia.Case Presentation: We report a ten-year-old girl who was admitted to the Department of Paediatrics, Endocrinology, Diabetology with Cardiology due to repeated seizures, hypoalcaemia with suspected...

hrp0089rfc1.4 | Adrenals & HPA Axis | ESPE2018

Mass Spectrometry-Based Assessment of Childhood Androgen Excess in 487 Consecutive Patients Over 5 Years

Idkowiak Jan , Elhassan Yasir S , Mannion Pascoe , Smith Karen , Webster Rachel , Saraff Vrinda , Barrett Timothy G , Shaw Nick J , Krone Nils , Dias Renuka P , Kershaw Melanie , Kirk Jeremy , Krone Ruth E , O'Reilly Michael W , Arlt Wiebke

Background: Androgen excess in childhood is a common clinical presentation and might signify serious pathology. We have recently explored patterns and severity of androgen excess in a large female adult cohort to differentiate common polycystic ovarian syndrome (PCOS) from non-PCOS pathology, including congenital adrenal hyperplasia (CAH), ovarian hyperthecosis and adrenal and ovarian tumours (Elhassan et al., JCE&M 2018). Herein, we undertake a similar approach f...

hrp0089p3-p398 | GH & IGFs P3 | ESPE2018

Recombinant Growth Hormone Therapy in Prepubertal Children with Idiopathic Short Stature in Korea: A Phase III Randomized Trial

Im Minji , Kim J , Suh B-K , Ko CW , Lee K-H , Shin CH , Hwang JS , Kim HS , Chung WY , Kim CJ , Han H-S , Kwon NY , Cho SY , Yoo H-W , Jin D-K

Several studies have evaluated the effects of growth hormone (GH) on auxological and biochemical parameters in children with non-GH-deficient, idiopathic short stature (ISS). This study evaluated the efficacy and safety of GrowtropinR-II (recombinant human GH) in Korean patients with ISS. This was a 1-year, open-label, multicenter, phase III randomized trial of Growtropin-II in Korean patients with ISS. In total, 70 prepubertal subjects (39 males, 31 females) betwee...